Primary Mitral Regurgitation

Similar documents
Guidelines in perspective?

Mitral Valve prolapse: What s new? Which indications of early surgery? Input of new 2017 ESC/EACTS guidelines. Christophe Tribouilloy Amiens, France

Les valvulopathies en sourdine: la valve mitrale Quoi faire devant une régurgitation mitrale sévère asymptomatique de type dégénérative?

Advanced Evaluation of Left Ventricular Function in Degenerative MR. Dr Julien Magne, PhD University of Liege, CHU Sart Tilman, Liege, Belgium

How to assess ischaemic MR?

Assessing Function by Echocardiography in VHD Asymptomatic Severe Organic MR. Dr. Julien Magne, PhD Sart Tilman Liège, BELGIUM

Chronic Primary Mitral Regurgitation

Exercise Pulmonary Hypertension predicts the Occurrence of Symptoms in Asymptomatic Degenerative Mitral Regurgitation

How does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? NO DISCLOSURE

The difficult patient with mitral regurgitation

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017

What echo measurements are key prior to MitraClip?

Valvular Regurgitation: Can We Do Better Than Colour Doppler?

Exercise Testing/Echocardiography in Asymptomatic AS

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

What is the Role of Surgical Repair in 2012

J Cardiovasc Med 2012, 13: Received 19 October 2011 Revised 8 November 2011 Accepted 29 November 2011

Asymptomatic Valvular Disease:

Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention

DECISION MAKING DEL CARDIOCHIRURGO NELL INSUFFICIENZA MITRALICA: ISTRUZIONI D USO D CARDIOLOGO

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

Functional Mitral Regurgitation

Secondary MR joint with the mitral academy. What is new in our understanding of this disease? Luc Pierard University Hospital, Liège

Load and Function - Valvular Heart Disease. Tom Marwick, Cardiovascular Imaging Cleveland Clinic

Natural History and Echo Evaluation of Aortic Stenosis

LV geometric and functional changes in VHD: How to assess? Mi-Seung Shin M.D., Ph.D. Gachon University Gil Hospital

New 3D Quantification of Mitral Regurgitation Severity. Judy Hung, MD Cardiac Ultrasound Laboratory Massachusetts General Hospital Boston, MA

MR echo case. N.Koutsogiannis Department of Cardiology University Hospital Of Patras

Clinical Outcome of Tricuspid Regurgitation. David Messika-Zeitoun

Spotlight on Valvular Heart Disease Guidelines

Organic mitral regurgitation

What are the best diagnostic tools to quantify aortic regurgitation?

Exercise-Induced Changes in Degenerative Mitral Regurgitation

Low Gradient Severe? AS

ESC/EACTS Guidelines for the Management of Valvular Heart Disease

Valvular Guidelines: The Past, the Present, the Future

Severe left ventricular dysfunction and valvular heart disease: should we operate?

Exercise PHT in valvular heart disease. Julien Magne CHU Limoges, France

LUST trial. Echocardiography USER S MANUAL

ASE Guidelines on Aortic Regurgitation What Do I Measure? Case Studies

Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F.

Indicator Mild Moderate Severe

When is it too late to perform transcatheter mitral valve repair? Alec Vahanian, FESC,FRCP(Edin.) Bichat hospital University Paris VII

Professors Carpentier and McGoon Mechanism, resulting from the disease Severity of regurgitation, resulting from the mechanism Echo

Prof. JL Zamorano Hospital Universitario Ramón y Cajal

Management of significant asymptomatic aortic stenosis. Alec Vahanian Bichat Hospital University Paris VII Paris, France

What Degree of MR Deserves Surgical or Transcatheter Intervention, and How Should It Be Assessed?

MITRAL REGURGITATION ECHO PARAMETERS TOOL

«Paradoxical» low-flow, low-gradient AS with preserved LV function: A Silent Killer

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid

Bogdan A. Popescu. University of Medicine and Pharmacy Bucharest, Romania. EAE Course, Bucharest, April 2010

Mitral Regurgitation

Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know

Marti McCulloch, BS, MBA, RDCS, FASE Houston, Texas

Secondary Mitral Regurgitation: When Should We Intervene?

Disclosures Rebecca T. Hahn, MD, FASE

I have financial relationships to disclose Honoraria from: Edwards

Επιδιόπθωζη μιηποειδικήρ ζςζκεςήρ ζε ππόπηωζη ή πήξη γλωσίνων. Βαζίλειορ Σασπεκίδηρ Επιμεληηήρ Β Καπδιολογίαρ Γ.Ν. Παπαγεωπγίος

Percutaneous Mitral Valve Repair

Echocardiography. Guidelines for Valve and Chamber Quantification. In partnership with

Prognostic Value of Left Atrial Size and Function

Echocardiographic evaluation of mitral stenosis

MITRAL VALVE PATHOLOGY WITH TRICUSPID REGURGITATION (AND PHT)

Ioannis Alexanian, MD, PhD Department of Cardiology General Hospital of Chest Diseases Sotiria Athens

Aortic stenosis with concomitant mitral regurgitation

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines

Σεμινάρια Ομάδων Εργασίας 2017 Ανεπάρκεια μιτροειδούς μυξωματώδους αιτιολογίας

Catheter-based mitral valve repair MitraClip System

2017 ESC/EACTS Guidelines for the management of valvular heart disease

Valvular Intervention

Cases of mitral valve causing mitral regurgitation: the MV prolapse spectrum CASE

Regurgitant Lesions. Bicol Hospital, Legazpi City, Philippines July Gregg S. Pressman MD, FACC, FASE Einstein Medical Center Philadelphia, USA

Management of TR in Patients Undergoing Mitral Interventions

Late secondary TR after left sided heart disease correction: is it predictibale and preventable

Echocardiographic Correlates of Pulmonary Artery Systolic Pressure

ECHOCARDIOGRAPHY DATA REPORT FORM

Imaging MV. Jeroen J. Bax Leiden University Medical Center The Netherlands Davos, feb 2015

Quality Outcomes Mitral Valve Repair

The best in heart valve disease Aortic valve stenosis

Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine

Direct Planimetry of Mitral Valve Regurgitation Orifice Area by Real-time 3D Transesophageal Echocardiography

Aortic Regurgitation & Aorta Evaluation

Disclosures. ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech

Ischemic Mitral Regurgitation

A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision

Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro

Failure of Guideline Adherence for Intervention in Patients With Severe Mitral Regurgitation

Aortic Regurgitation and Aortic Aneurysm - Epidemiology and Guidelines -

Mitral Valve Prolapse and Sudden Death. JF Avierinos Hôpital Timone Marseille January 27th, 2017

What s New in the Guidelines for Surgical Ablation for Atrial Fibrillation?

The Key Questions in Mitral Valve Interventions. Where Are We in 2018?

Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan

ECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction

Quantification of Mitral Stenosis: Planimetry, pressure Half time, Continuity Common Errors

Valvular Heart Disease: Assessment and Timing of Intervention. Graham Cole Consultant Cardiologist Imperial College Healthcare NHS Trust

Understanding the guidelines for Interventions in MR. Ali AlMasood

Quantification of Aortic Regurgitation

HEART VALVE DISEASES. Dr. James Kadouch Medical Officer Cardiologist Delphine Labojka Method & Process Manager

Tricuspid and Pulmonary Valve Disease

Transcription:

EURO VALVE Madrid News from Valves Guidelines 2012: What s new and Why? Primary Mitral Regurgitation Luc A. Pierard, MD, PhD Professor of Medicine Head of the Department of Cardiology Heart Valve Clinic, University of Liège, CHU Sart Tilman, BELGIUM European Heart Journal 2012 - doi:10.1093/eurheartj/ehs109 European Journal of Cardio-Thoracic Surgery 2012 - doi:10.1093/ejcts/ezs455

Disclosure related to this presentation: None European Heart Journal 2012 - doi:10.1093/eurheartj/ehs109 European Journal of Cardio-Thoracic Surgery 2012 - doi:10.1093/ejcts/ezs455

What is new in 2012? The term primary replaces structural / organic European Heart Journal 2012 - doi:10.1093/eurheartj/ehs109 European Journal of Cardio-Thoracic Surgery 2012 - doi:10.1093/ejcts/ezs455

Echocardiographic criteria for the definition of severe MR: an integrative approach Parameters Qualitative Mitral valve morphology Colour flow MR jet (should no longer be measured) Severe Flail leaflet/ ruptured PMs Very large central jet or eccentric jet adhering, swirling and reaching the posterior LA wall Flow convergence zone CW signal of MR jet Large Dense/Triangular Lancellotti et al, Eur J Echo 2010 European Heart Journal 2012 - doi:10.1093/eurheartj/ehs109 European Journal of Cardio-Thoracic Surgery 2012 - doi:10.1093/ejcts/ezs455

Echocardiographic criteria for the definition of severe MR: an integrative approach Parameters Severe Semi-quantitative VC width (mm) Pulmonary vein flow Mitral inflow TVI mit/tvi Ao Quantitative EROA (mm²) R Vol (ml) 7 (>8 for biplane) Systolic flow reversal E wave dominant (>1.5 m/s) 1.4 40 for primary 60 for primary Lancellotti et al, Eur J Echo 2010

Indications for surgery in symptomatic primary MR Mitral valve repair should be the preferred technique when it is expected to be durable. Surgery is indicated in symptomatic patients with LVEF > 30% and LVESD < 55 mm. Surgery should be considered in patients with severe LV dysfunction (LVEF < 30% and/or LVESD > 55 mm) refractory to medical therapy with high likelihood of durable repair and low comorbidity. Surgery may be considered in patients with severe LV dysfunction (LVEF < 30% and/or LVESD > 55 mm) refractory to medical therapy with low likelihood of durable repair and low comorbidity. Class I I IIa IIb Level C B C C

Survival after repair vs replacement

Operative mortality after surgery for MR

The valve and the surgeon

Volume rates and Mitral Valve Repair STS Database: Gammie et al., Circ, 2007; Gammie et al., ATS, 2005.

Mitral Repair: We Must Do Better Many surgeons do not routinely repair mitral valves Non repair surgeons do not routinely cross refer Patients with predictable complex repair should undergo surgery in experienced repair centres with high repair rates and low operative mortality Lack of consistency in surgical repair in complex mitral valve morphology: rheumatic lesions, extensive valve prolapse, MR with leaflet calcification or extensive annulus calcification Dedicated MR teams could change practice Northrup. Heart 2006;92:939-944

Indications for surgery in symptomatic primary MR NOT NEW Mitral valve repair should be the preferred technique when it is expected to be durable. Surgery is indicated in symptomatic patients with LVEF > 30% and LVESD < 55 mm. Surgery should be considered in patients with severe LV dysfunction (LVEF < 30% and/or LVESD > 55 mm) refractory to medical therapy with high likelihood of durable repair and low comorbidity. Surgery may be considered in patients with severe LV dysfunction (LVEF < 30% and/or LVESD > 55 mm) refractory to medical therapy with low likelihood of durable repair and low comorbidity. Class I I IIa IIb Level C B C C

Impact of symptoms and LV dysfunction following mitral surgery Symptoms LV dysfunction -28% -19% -19% Enriquez-Sarano et al. Circulation, 90: 830-7; 1994

Indications for surgery in asymptomatic severe primary MR Surgery is indicated in asymptomatic patients with LV dysfunction (LVESD 45 mm and/or LVEF 60%). Surgery should be considered in asymptomatic patients with preserved LV function and new onset of atrial fibrillation or pulmonary hypertension (SPAP at rest > 50 mmhg). Surgery should be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk and flail leaflet and LVESD 40 mm ( 22 mm/m 2 BSA in patients of small stature). Surgery may be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk, and: left atrial dilatation (volume index 60 ml/m² BSA) and sinus rhythm, or pulmonary hypertension on exercise (SPAP 60 mmhg at exercise) Class Level I C IIa C IIa C IIb C

Impact of MR severity Enriquez-Sarano et al N Engl J Med 2005;352:875-83

Quantitative measurements Hemispheric PISA Dynamic changes

Indications for surgery in asymptomatic severe primary MR Surgery is indicated in asymptomatic patients with LV dysfunction (LVESD 45 mm and/or LVEF 60%). NOT NEW Surgery should be considered in asymptomatic patients with preserved LV function and new onset of atrial fibrillation or pulmonary hypertension (SPAP at rest > 50 mmhg). Surgery should be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk and flail leaflet and LVESD 40 mm ( 22 mm/m 2 BSA in patients of small stature). Surgery may be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk, and: left atrial dilatation (volume index 60 ml/m² BSA) and sinus rhythm, or pulmonary hypertension on exercise (SPAP 60 mmhg at exercise) Class Level I C IIa C IIa C IIb C

LV EDV = 250 ml LV ESV = 50 ml LV ejection fraction = 80% Regurgitation fraction = 56% Forward ejection fraction = 24%

LV Remodeling in primary MR

Indications for surgery in asymptomatic primary MR Surgery is indicated in asymptomatic patients with LV dysfunction (LVESD 45 mm and/or LVEF 60%). Surgery should be considered in asymptomatic patients with preserved LV function and new onset of atrial fibrillation or pulmonary hypertension (SPAP at rest > 50 mmhg). Surgery should be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk and flail leaflet and LVESD 40 mm ( 22 mm/m 2 BSA in patients of small stature). Surgery may be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk, and: left atrial dilatation (volume index 60 ml/m² BSA) and sinus rhythm, or pulmonary hypertension on exercise (SPAP 60 mmhg at exercise) Class Level I C IIa C IIa C IIb C

Incidence of AF in primary MR Rate of AF also increases with age Grigioni J Am Coll Cardiol 2002;40:84 Messika-Zeitoun, EHJ 2007 28:1773

Survival of patients with flail leaflets and atrial fibrillation Onset of AF is associated with CV morbidity Onset of AF predicted death Avierinos Circ 2002;106:1355 Grigioni J Am Coll Cardiol 2002;40:84

Symptom-free survival, % Pulmonary hypertension at rest 100 80 60 40 20 p=0.04 59±7% 36±14% No resting PHT Resting PHT Adjusted HR=2.1, p=ns 0 0 6 12 18 24 30 36 42 48 Follow-up, months Magne J, Lancellotti P, Piérard LA. Circulation, 2010, 122: 33-41

Indications for surgery in asymptomatic primary MR Surgery is indicated in asymptomatic patients with LV dysfunction (LVESD 45 mm and/or LVEF 60%). Surgery should be considered in asymptomatic patients with preserved LV function and new onset of atrial fibrillation or pulmonary hypertension (SPAP at rest > 50 mmhg). Surgery should be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk and flail leaflet and LVESD 40 mm ( 22 mm/m 2 BSA in patients of small stature). NEW Surgery may be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk, and: left atrial dilatation (volume index 60 ml/m² BSA) and sinus rhythm, or pulmonary hypertension on exercise (SPAP 60 mmhg at exercise) Class Level I C IIa C IIa C IIb C

Impact of LV dimension on survival MIDA registry 739 patients with flail leaflet, follow-up: 6.1±3.7 years 739 patients with flail leaflet, follow-up: 6.1±3.7 years Conservative Management Medical + Surgery Tribouilloy et al. JACC, 2009;54:1961 8

Hazard Ratio Impact of LV Dilatation on Survival MIDA registry 10 33% of asymptomatic pts with LVESD > 40mm 3.2 1.0 0.3 40 or 22 mm/m² 30 35 40 45 50 LV ESD (mm) Tribouilloy et al. JACC, 2009;54:1961 8

Indications for surgery in asymptomatic primary MR Surgery is indicated in asymptomatic patients with LV dysfunction (LVESD 45 mm and/or LVEF 60%). Surgery should be considered in asymptomatic patients with preserved LV function and new onset of atrial fibrillation or pulmonary hypertension (SPAP at rest > 50 mmhg). Surgery should be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk and flail leaflet and LVESD 40 mm ( 22 mm/m 2 BSA in patients of small stature). Surgery may be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk, and: NEW left atrial dilatation (volume index 60 ml/m² BSA) and SR pulmonary hypertension on exercise (SPAP 60 mmhg) Class Level I C IIa C IIa C IIb C

LA volume Le Tourneau et al JACC 2010;56:570-8.

Prevalence of pulmonary hypertension at rest and at exercise in asymptomatic primary MR Magne J, Lancellotti P, Piérard LA. Circulation, 2010, 122: 33-41

Symptom-free survival, % Exercise pulmonary hypertension 100 Exercise PHT (SPAP > 60mmHg) 80 60 75±7 % No exercise PHT 40 20 p<0.0001 35±8 % Exercise PHT 0 0 6 12 18 24 30 36 42 48 Follow-up, months Adjusted HR=2.8, p=0.01 Magne J, Lancellotti P, Piérard LA. Circulation, 2010, 122: 33-41

Sensitivity PHT to predict the onset of symptoms 100 80 60 40 20 0 ROC curves 0 20 40 60 80 100 100-Specificity p=0.032 Exercise SPAP Resting SPAP Exercise SPAP >56mmHg Exercise SPAP >60mmHg Resting SPAP >36mmHg Resting SPAP >50mmHg Prediction of symptoms Variables Sensi. Specif. Exercise SPAP >56mmHg 82 73 Exercise SPAP >60mmHg 71 78 Resting SPAP >36mmHg 72 56 Resting SPAP >50mmHg 25 95 AUC: 0.67 vs. 0.77 p=0.032

Summary: What is new? - ESC + EACTS - Important role of heart team - Primary rather than structural - New onset of atrial fibrillation: IIa - LVESD 40 mm when flail leaflet: IIa - LA volume 60 ml/m²: IIb - SPAP 60 mmhg at exercise: IIb